{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-030184","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.962389+00:00","generated_at":"2026-05-17T05:05:29.821533+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Pulse Biosciences stockholders approve equity plan amendment and ratify director options","bullets":["Stockholders approved increasing Equity Plan shares by 2 million and changing Consultant definition.","Ratified options for up to 1.1 million shares, including 600,000 to directors (CEO LaViolette).","Director options have exercise price $15.65, 10-year term, vesting over annual meeting and monthly.","Proposal 1 voted 50,247,945 For vs 2,753,901 Against; Proposal 2 similarly approved.","Special Meeting held Sept 30, 2025; quorum of 53,011,701 shares represented."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-030184","json":"https://secwatch.observer/filing/0001437749-25-030184.json","markdown":"https://secwatch.observer/filing/0001437749-25-030184.md","text":"https://secwatch.observer/filing/0001437749-25-030184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925030184/0001437749-25-030184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925030184/plse20250929_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:05:29.821533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}